\BOOKMARK [0][-]{chapter*.1}{Abstract}{}% 1
\BOOKMARK [0][-]{chapter*.2}{Preface}{}% 2
\BOOKMARK [0][-]{chapter*.3}{Table of Contents}{}% 3
\BOOKMARK [0][-]{chapter*.4}{List of Tables}{}% 4
\BOOKMARK [0][-]{chapter*.5}{List of Figures}{}% 5
\BOOKMARK [0][-]{chapter*.6}{Glossary}{}% 6
\BOOKMARK [0][-]{chapter*.7}{Acknowledgments}{}% 7
\BOOKMARK [0][-]{chapter.1}{1 Introduction}{}% 8
\BOOKMARK [1][-]{section.1.1}{1.1 Objectives}{chapter.1}% 9
\BOOKMARK [1][-]{section.1.2}{1.2 Genomics-Driven Oncology}{chapter.1}% 10
\BOOKMARK [2][-]{subsection.1.2.1}{1.2.1 Definition}{section.1.2}% 11
\BOOKMARK [1][-]{section.1.3}{1.3 Massively Parallel Sequencing}{chapter.1}% 12
\BOOKMARK [2][-]{subsection.1.3.1}{1.3.1 Massively Parallel Sequencing Technologies}{section.1.3}% 13
\BOOKMARK [2][-]{subsection.1.3.2}{1.3.2 Applications of Massively Parallel Sequencing}{section.1.3}% 14
\BOOKMARK [2][-]{subsection.1.3.3}{1.3.3 Whole Exome Sequencing}{section.1.3}% 15
\BOOKMARK [2][-]{subsection.1.3.4}{1.3.4 Whole Genome Sequencing}{section.1.3}% 16
\BOOKMARK [1][-]{section.1.4}{1.4 Bioinformatics Tools for Variant Calling}{chapter.1}% 17
\BOOKMARK [2][-]{subsection.1.4.1}{1.4.1 Types of Genomic Alterations}{section.1.4}% 18
\BOOKMARK [2][-]{subsection.1.4.2}{1.4.2 Variant Calling Pipeline}{section.1.4}% 19
\BOOKMARK [2][-]{subsection.1.4.3}{1.4.3 Variant Calling Algorithms}{section.1.4}% 20
\BOOKMARK [2][-]{subsection.1.4.4}{1.4.4 Variant Curation and Interpretation}{section.1.4}% 21
\BOOKMARK [1][-]{section.1.5}{1.5 Challenges in Clinical Genomics}{chapter.1}% 22
\BOOKMARK [2][-]{subsection.1.5.1}{1.5.1 DNA Damage by Formalin Fixation}{section.1.5}% 23
\BOOKMARK [2][-]{subsection.1.5.2}{1.5.2 Lack of Matched Normal DNA}{section.1.5}% 24
\BOOKMARK [2][-]{subsection.1.5.3}{1.5.3 Variant of Unknown Significance}{section.1.5}% 25
\BOOKMARK [2][-]{subsection.1.5.4}{1.5.4 Incidental Findings}{section.1.5}% 26
\BOOKMARK [1][-]{section.1.6}{1.6 Pharmacogenomics in Clinical Oncology}{chapter.1}% 27
\BOOKMARK [2][-]{subsection.1.6.1}{1.6.1 Targeted Therapies}{section.1.6}% 28
\BOOKMARK [2][-]{subsection.1.6.2}{1.6.2 Chemotherapy-Associated Morbidities}{section.1.6}% 29
\BOOKMARK [1][-]{section.1.7}{1.7 Summary}{chapter.1}% 30
\BOOKMARK [0][-]{chapter.2}{2 Germline Pharmacogenomics Testing in Formalin-Fixed Paraffin-Embedded Tumours}{}% 31
\BOOKMARK [1][-]{section.2.1}{2.1 Overview}{chapter.2}% 32
\BOOKMARK [1][-]{section.2.2}{2.2 Methods}{chapter.2}% 33
\BOOKMARK [1][-]{section.2.3}{2.3 Results and Discussion}{chapter.2}% 34
\BOOKMARK [0][-]{chapter.3}{3 Conclusion}{}% 35
\BOOKMARK [0][-]{chapter*.9}{Bibliography}{}% 36
\BOOKMARK [0][-]{appendix.A}{A Supporting Materials}{}% 37
